← CSPC Innovation Pharmaceutical overview

CSPC Innovation Pharmaceutical vs Srinanaporn Marketing: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

CSPC Innovation Pharmaceutical Co Ltd Class A (300765.CS)

Q3 202616 Jul – 14 Sep 2026

▲3

CSPC Innovation Swings to Profit as Cancer Drug Pipeline Hits Key Milestones

Interim profit turnaround confirms commercial ramp CSPC Innovation reported a first-half net profit of 1.261 billion yuan, reversing a year-ago loss, with revenue up 208.7% to 3.24 billion yuan and a 76.7% gross margin. This shows the biopharma business is now generating real cash and earnings, which supports the stock's valuation.
The swing to profit is the clearest fundamental driver of the stock's value and confirms the business is no longer loss-making.
SYS6010 Phase III success and strong lung cancer data SYS6010 met its main goal in a Phase III lung cancer trial, and new data showed it combined with another drug shrank tumors in up to 82.4% of high-PD-L1 patients. These results raise the odds of approval and future sales, boosting investor confidence.
This is the most advanced pipeline asset with late-stage success, directly increasing the probability of a major new revenue stream.
Two new drug applications advance toward market A marketing application for a HER2 ADC for breast cancer was accepted, and a Phase III trial for a B7-H3 ADC in ovarian cancer began. Both move the company closer to adding new approved products, which would broaden future revenue.
These regulatory and clinical steps expand the pipeline and signal more near-term product launches.

August 202616 Jul – 14 Sep 2026

▲3

CSPC Innovation Swings to Profit as Cancer Drug Pipeline Hits Key Milestones

Interim profit turnaround confirms commercial ramp CSPC Innovation reported a first-half net profit of 1.261 billion yuan, reversing a year-ago loss, with revenue up 208.7% to 3.24 billion yuan and a 76.7% gross margin. This shows the biopharma business is now generating real cash and earnings, which supports the stock's valuation.
The swing to profit is the clearest fundamental driver of the stock's value and confirms the business is no longer loss-making.
SYS6010 Phase III success and strong lung cancer data SYS6010 met its main goal in a Phase III lung cancer trial, and new data showed it combined with another drug shrank tumors in up to 82.4% of high-PD-L1 patients. These results raise the odds of approval and future sales, boosting investor confidence.
This is the most advanced pipeline asset with late-stage success, directly increasing the probability of a major new revenue stream.
Two new drug applications advance toward market A marketing application for a HER2 ADC for breast cancer was accepted, and a Phase III trial for a B7-H3 ADC in ovarian cancer began. Both move the company closer to adding new approved products, which would broaden future revenue.
These regulatory and clinical steps expand the pipeline and signal more near-term product launches.

Latest16 Jul – 14 Sep 2026

▲3

CSPC Innovation Swings to Profit as Cancer Drug Pipeline Hits Key Milestones

Interim profit turnaround confirms commercial ramp CSPC Innovation reported a first-half net profit of 1.261 billion yuan, reversing a year-ago loss, with revenue up 208.7% to 3.24 billion yuan and a 76.7% gross margin. This shows the biopharma business is now generating real cash and earnings, which supports the stock's valuation.
The swing to profit is the clearest fundamental driver of the stock's value and confirms the business is no longer loss-making.
SYS6010 Phase III success and strong lung cancer data SYS6010 met its main goal in a Phase III lung cancer trial, and new data showed it combined with another drug shrank tumors in up to 82.4% of high-PD-L1 patients. These results raise the odds of approval and future sales, boosting investor confidence.
This is the most advanced pipeline asset with late-stage success, directly increasing the probability of a major new revenue stream.
Two new drug applications advance toward market A marketing application for a HER2 ADC for breast cancer was accepted, and a Phase III trial for a B7-H3 ADC in ovarian cancer began. Both move the company closer to adding new approved products, which would broaden future revenue.
These regulatory and clinical steps expand the pipeline and signal more near-term product launches.

Srinanaporn Marketing Public Company Limited (SNNP.BK)

Q3 202620 Jul – 9 Oct 2026

▲3▼1

SNNP's profit has bottomed out; recovery, stimulus and new products drive gains

Profit trough passed, brokers raise targets Brokers say SNNP's profit bottomed in early 2026 and is now recovering. Q2 profit of 69.8 million baht rose 23% from the prior quarter, helped by Vietnam sales and steady 26% gross margin. Several houses upgraded to buy with targets of 8-9 baht, lifting the shares.
This is the core reason the stock is moving: earnings have stopped falling and analysts have turned positive.
New products and brand tie-ups broaden sales SNNP launched Jele Chewy fruit-tea jelly with Kamu Kamu, a sports jelly with Alpine, and a new Bento ad campaign. These push into younger and health-focused buyers, and the Jele tie-up got a better-than-expected response, prompting restocking and supporting sales into the high season.
New products and partnerships are a main growth engine behind the expected revenue recovery.
Government stimulus and Vietnam growth lift demand Thailand's Thai Help Thai Plus Phase 2 gives 1,000 baht of co-payment spending in October-November, and SNNP earns about 70-79% of revenue at home, so it benefits. Vietnam's economy grew 9.95% in Q3, and SNNP's Vietnam revenue is expected to rise 17% this year.
These are the demand-side forces expected to drive the second-half recovery.
Factory fire adds supply risk A fire hit SNNP's Bento snack building on 9 October. No one was hurt and insurance should cover the damage, but output is disrupted. The company has about one month of inventory and can use its Vietnam plant, so the revenue hit is seen as limited.
This is the main counterweight to the positive recovery story and a real risk to near-term supply.

August 202620 Jul – 9 Oct 2026

▲3▼1

SNNP's profit has bottomed out; recovery, stimulus and new products drive gains

Profit trough passed, brokers raise targets Brokers say SNNP's profit bottomed in early 2026 and is now recovering. Q2 profit of 69.8 million baht rose 23% from the prior quarter, helped by Vietnam sales and steady 26% gross margin. Several houses upgraded to buy with targets of 8-9 baht, lifting the shares.
This is the core reason the stock is moving: earnings have stopped falling and analysts have turned positive.
New products and brand tie-ups broaden sales SNNP launched Jele Chewy fruit-tea jelly with Kamu Kamu, a sports jelly with Alpine, and a new Bento ad campaign. These push into younger and health-focused buyers, and the Jele tie-up got a better-than-expected response, prompting restocking and supporting sales into the high season.
New products and partnerships are a main growth engine behind the expected revenue recovery.
Government stimulus and Vietnam growth lift demand Thailand's Thai Help Thai Plus Phase 2 gives 1,000 baht of co-payment spending in October-November, and SNNP earns about 70-79% of revenue at home, so it benefits. Vietnam's economy grew 9.95% in Q3, and SNNP's Vietnam revenue is expected to rise 17% this year.
These are the demand-side forces expected to drive the second-half recovery.
Factory fire adds supply risk A fire hit SNNP's Bento snack building on 9 October. No one was hurt and insurance should cover the damage, but output is disrupted. The company has about one month of inventory and can use its Vietnam plant, so the revenue hit is seen as limited.
This is the main counterweight to the positive recovery story and a real risk to near-term supply.

Latest20 Jul – 9 Oct 2026

▲3▼1

SNNP's profit has bottomed out; recovery, stimulus and new products drive gains

Profit trough passed, brokers raise targets Brokers say SNNP's profit bottomed in early 2026 and is now recovering. Q2 profit of 69.8 million baht rose 23% from the prior quarter, helped by Vietnam sales and steady 26% gross margin. Several houses upgraded to buy with targets of 8-9 baht, lifting the shares.
This is the core reason the stock is moving: earnings have stopped falling and analysts have turned positive.
New products and brand tie-ups broaden sales SNNP launched Jele Chewy fruit-tea jelly with Kamu Kamu, a sports jelly with Alpine, and a new Bento ad campaign. These push into younger and health-focused buyers, and the Jele tie-up got a better-than-expected response, prompting restocking and supporting sales into the high season.
New products and partnerships are a main growth engine behind the expected revenue recovery.
Government stimulus and Vietnam growth lift demand Thailand's Thai Help Thai Plus Phase 2 gives 1,000 baht of co-payment spending in October-November, and SNNP earns about 70-79% of revenue at home, so it benefits. Vietnam's economy grew 9.95% in Q3, and SNNP's Vietnam revenue is expected to rise 17% this year.
These are the demand-side forces expected to drive the second-half recovery.
Factory fire adds supply risk A fire hit SNNP's Bento snack building on 9 October. No one was hurt and insurance should cover the damage, but output is disrupted. The company has about one month of inventory and can use its Vietnam plant, so the revenue hit is seen as limited.
This is the main counterweight to the positive recovery story and a real risk to near-term supply.